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ABSTRACT
Back-ground An association between the use of
oral contraceptives and the risk of myocardial infarc-
tion has been found in some, but not all, studies. We
investigated this association, according to the type of
progestagen included in third-generation (i.e., deso-
gestrel or gestodene) and second-generation (i.e., le-
vonorgestrel) oral contraceptives, the dose of estro-
gen, and the presence or absence of prothrombotic
mutations.
Methods In a nationwide, population-based, case-
control study, we identified and enrolled 248 women
18 through 49 years of age who had had a first myo-
cardial infarction between 1990 and 1995 and 925 con-
trol women who had not had a myocardial infarction
and who were matched for age, calendar year of the
index event, and area of residence. Subjects supplied
Information on oral-contraceptive use and major car-
diovascular risk factors. An analysis for factor V Leiden
and the G20210A mutation in the prothrombin gene
was conducted in 217 patients and 763 controls.
Results The odds ratio for myocardial infarction
among women who used any type of combined oral
contraceptive, äs compared with nonusers, was 2.0 (95
percent confidence interval, 1.5 to 2.8). The adjusted
odds ratio was 2.5 (95 percent confidence interval, 1.5
to 4.1) among women who used second-generation
oral contraceptives and 1.3 (95 percent confidence in-
terval, 0.7 to 2.5) among those who used third-gener-
ation oral contraceptives. Among women who used
oral contraceptives, the odds ratio was 2.1 (95 percent
confidence interval, 1.5 to 3.0) for those without a pro-
thrombotic mutation and 1.9 (95 percent confidence
interval, 0.6 to 5.5) for those with a mutation.
Conclusions The risk of myocardial infarction was
increased among women who used second-genera-
tion oral contraceptives. The results with respect to
the use of third-generation oral contraceptives were
inconclusive but suggested that the risk was Iower
than the risk associated with second-generation oral
contraceptives. The risk of myocardial infarction was
similar among women who used oral contraceptives
whether or not they had a prothrombotic mutation.
(N Engl J Med 2001;345:1787-93.)
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T
l HE first report of coronary thrombosis as-
sociated with the use of oral contraceptives
appeared in 1963.1 Later studies established
the use of oral contraceptives äs a risk factor
for venous äs well äs arterial thrombosis.2 7 Various
modifications were made in an attempt to Iower these
risks, including a reduction in the estrogen dose and
changes in the progestagen compound. Oral contra-
ceptives containing an estrogen and the progestagen
desogestrel or gestodene, available since the 1980s,
are associated with at least a doubling of the risk of
venous thrombosis äs compared with other combined
oral contraceptives.812 It has been suggested that these
third-generation contraceptives protect against myo-
cardial infarction by having a favorable effect on the
lipid profile,131S because studies showed that women
who used these types had a slight increase in the level
of high-density lipoprotein cholesterol.15·16 Only a few
studies of the association between oral contraceptives
and myocardial infarction have included a direct com-
parison of third- and second-generation progestagens,
and the results have been contradictory.17 21 We inves-
tigated whether the use of low-dose combined oral
contraceptives affects the risk of myocardial infarction.
We assessed the effect of the type of progestagen in-
cluded in the oral contraceptive (levonorgestrel äs
compared with gestodene or desogestrel), the dose
of estrogen, and the presence of the G1691A muta-
tion in the factor V gene (factor V Leiden) and the
G20210A mutation in the prothrombin gene, which
have been associated with myocardial infarction in
young women22'23 äs well äs with a particularly high
Fiom the Thrombosis and Hemostasis Reseaich Center, Department of
Hcmatology (B CT, FR R), and the Departmcnts of Cardiology (VM C ),
Obstctrics, Gynccology, and Reproductive Medicmc (FM H ), and Clmical
Epidemiology (FR R), Leiden Umveisity Medical Center, Leiden, and
the Julius Center foi General Practice and Patient Onented Research
(M A A J B , J M K , A A , YG ) and the Department of Neurology (A A ),
Umversity Medical Center, Utiecht — both in the Ncthcrlands Addrcss
icprmt lequcsts to Dr Roscndaal at the Department of Clmical Epidenn
ology, Leiden Umveisity Mcdical Center, Bldg l, C9 P, PO Box 9600, 2300
RC Leiden, the Netherlands, or at f nosendaalOlumc nl
The New England Journal of Mechcme




The Risk of Aiterial Thrombosis in Relation to Oial Contracep
tives (RATIO) smdy is a population based case-control study of die
relaöon of aiteual disease to the use of oial contraceptives among
women 18 to 49 years of age in the Netheilands The study proto
col was approved by the ethics committees of die participating hos
pitals (see the Appendix) Oial informed consent was obtained from
all participants
Identification of Women with Myocardial Infarction
Ehgible patients wcre women 18 to 49 years of age who were
hospitalized foi a first myocardial mfarction between January 1990
and Octobei 1995 Mvocaidial mfarction was defined by the pres
ence of Symptoms, elcvated cardiac enzyme levels, and electrocai
diogiapliic changes K The patients were idenüfied through a search
of computerized hospital data bases foi International Classification
ofDiseases, 9th Revision, Clmical Modification codes for acute my
ocardial mfarction Of the 321 womeii who weie admitted to the
16 participating centeis durmg this penod, 29 (9 percent) were
excluded 19 died durmg adnussion, 9 died between discharge and
die Start of the study, and l was unable to partiupate The med
ical records of all patients were reviewed by one mvestigatoi Of
die 292 lemaimng patients, 21 could not be located and 23 declined
to participate (icsponse rate, 85 percent)
Control Women
The study was designed to investigate three types of aitenal
disease myocardial mfarction, ischemic stroke, and penpheral ar-
tenal disease, the icsults for each type are repoited separately We
idenüfied and recruited one laige control group through random
digit dialing 26 In tliis method, pnvate telephone iiumbers random
ly generated by a Computer are dialed untü someone answeis 01 at
least seven attempts have been made at vanous times of die day and
the weck, includmg the weckend We icached someone at 98 pei
cent of the iiumbeis aftcr a total of 15,725 telephone calls Once
it was asceitamed that a household mcluded a woman who was
ehgible for die study, she was asked to participate We reciuited con
tiol women from the six geographic aieas where the patients hved,
and usmg questionnanes, we assigned each an mdex year corie
spondmg to the one of the six years (1990 to 1995) in which the
patients had had an mdex event Therefore, a contiol woman lau
domly leceived one of six questionnaues conceimng one of the
inde\ yeais All questions clicited Information about either the in
dex date (in the case of questions about die body mass mde\, mcn
opausal Status, level of educatioii, and family history), the yeai before
the mdex date (in the case of questions about a histoiy of hypei
tensioii, diabetes, hypeicholesteiolemia, alcohol use, and smokmg),
01 the moiith befoie die mdex date (m the case of questions about
the use of oial contiaccptives) l he mdex date was the date of the
myocaidial mfaiction m the patients and midycar m the contiols
Γο mimmize age diffeiences between the patients and the contiols,
contiol women m the oldei age gioups were oveisampled by m
cieasmg the age limit of eligibility cntena durmg icuuitment The
contiol gioup dieiefoie was a population sample stratified aecoiding
to age (in five yeai categones), area of lesidence, and calcndai year
Ehgible contiols weie women 18 to 49 veais of age who had no
histoiy of coionary, ceiebial, or penpheial aiteual disease A total
of 1259 ehgible women weie icached by random digit dialing, 925
of whom agieed to paiticipate and retuined the questionnaire (73
peicent)
Data Collection
The standardized questionnaire that was mailed to patients and
controls included questions about demographics, use of oral contra
ceptives, repioductive history, heiglit and weight, and the piesence
01 absence of a history of hypertension, diabetes, hypeicholesteiol
emia, and cigarctte smokmg and a family history of caidiovascular
diseast Color photographs of all oial-contiaceptive puls marketed
in the Netheilands duimg the study penod weie included to help
women leeall the foimulations they might have used Oial con
tiaceptives were divided mto foui gioups aecoiding to die type of
progestagens included fiist-generation foimulations contaming
lynestrenol or norethindrone, second-geneiation foimulations con
taimng levonorgestrel, thnd generation formulations contammg
desogestiel or gestodene, and oial contiaceptives contaming an es
tiogen and other progestagens (cyproteionc 01 noigestimate) 01 a
progestagen alone We also classified oial conti aceptives aecoiding
to die dose of estrogen Womeii weie categonzed aecoiding to dieir
use of oral conti aceptives (never, former, or cunent) The level of
education was categonzed äs pnmaiy school 01 less, secondaiy
school, 01 highci education or umveisity Obesity was defined äs
a body mass mdex (the weight m kilogiams divided by the squaie
of the heiglit m meters) of at least 273 " Women were classified
äs havmg hypertension, diabetes, or hypercholesteiolemia when they
reported that the condition had beeil diagnosed by a physician 01
that they had been taking medication for the condition befoie die
Index date Smoking Status was categonzed äs nevei, foimei, 01 cui
icnt Current smokers weie diose who icpoited smoking 111 the year
betöre the mdex date Alcohol use was categonzed äs none, l to
15 dimks per week, and more than 15 dnnks per week A family
history of cardiovasculai disease was defined äs the occuircnce of
myocardial mfarction, stioke, or penpheral arteiial disease befoie
the age of 60 yeais in one or more fast degree relatives
Samples of venous blood or buccal swabs were obtamcd hom
217 patients (88 percent) and 763 contiols (82 percent) who
consented to undergo DNA analysis foi factor V Leiden and the
G20210A mutation in die prodirombin gciie The polymerasc cham
icaction was used for the analysis 2728
Statistical Analysis
We used uncoiiditional logistic-regression analyses to calculate
odds latios foi die relation between the use of oral contraceptives
and myocardial mfarction, and we denved confidence intervals from
the model We adjusted for the tlnee stratification faetois — age
(m five year categories), aiea of lesidence, and calendai yeai — and
foi putative confoundmg factors (smokmg Status, piesence 01 ab
sence of hypercholesterolemia, diabetes, hypei tension, obesity, and
a family history of cardiovasculai disease, level of education, and
alcohol mtake) To exclude an effect of die dose of estiogen m the
analyses that were focused on the type of piogestagen mcluded
m the oial conti aceptivc, we excluded womeii who used foimu
lations othei than those contaming 30 μζ of etlnnyl estiadiol 28
women (13 patients and 15 contiols) used second geneiation oial
conti aceptives contaming 50 /ug of ethmyl cstiacliol, 67 women
(13 patients and 54 eoiitiols) used tnphasic second geneiation
oial contiacepuves, 3 women (all contiols) vised tiiphasic thnd
geneiation oial conti aceptives, 18 women (2 patients and 16 con
tiols) used thnd geneiation oial conti aceptives contaming 20 ßg
of ethmyl estiadiol, and m 6 women (l patient and 5 contiols)
the dose of ethmvl estradiol was unknown In a fuithei effoit to
mmmiize the possibihty of confoundmg, in paiticulai by the
piesence of pieexistmg disease, wc icpeated the analysis aftei ex
cluding womeii with majoi caidiovasculai iisk faetois We also dl
rectl) investigatcd whethci confoundmg was piesent, m paiticulai
piesciiption blas, by analyzing iisk faetois and oial contraceptive
use in the control women Analyses of the dose of ctlunyl csti a
diol weie lestnctcd to women who used oial conti aceptives con
taimng 50 μ-g of ethmyl estiadiol and 150 /xg of levonoigestiel
01 30 /ig of ethmyl estiadiol and 125 /ng of levonoigestiel Fi
nally, we assessed the effect of combmations of nsk faetois the
use of oral contraceptives and conventional iisk faetois (cuirent
smolang, hypeicholesterolemia, diabetes, and hypertension), äs well
äs factoi V Leiden and die G20210A mutation m the piothiom
bin gene
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RESULTS
Table l shows the characteristics of the 248 wom-
en who had had a myocardial infarction and the 925
control women. Patients ranged in age from 24 to 49
years (mean, 43), and controls ranged in age from 18
to 49 years (mean, 38). Patients had a higher prev-
alence than controls of major risk factors for cardio-
vascular disease, such äs hypertension (24 percent vs.
6 percent), hypercholesterolemia (11 percent vs. 3 per-
cent), diabetes (6 percent vs. l percent), and current
smoking (84 percent vs. 43 percent). Patients also had
a lower level of education thari controls (11 percent vs.
27 percent with post-secondary-school education).
The risk of myocardial infarction amorig users of
any type of oral contraceptive was twice that ofnon-
users (95 percent confidence interval, 1.5 to 2.8), af-
ter adjustment for age, calendar year, and area of res-
idence (Table 2). Additional adjustment for putative
confounding factors increased the odds ratio in most
age categories, and the Overall risk remained dou-
bled (Table 2). Women with no conventional risk
factors (hypertension, hypercholesterolemia, diabetes,
or smoking) who used oral contraceptives had a rel-
ative risk of myocardial infarction of 3.1 (95 percent
confidence interval, 1.0 to 9.2). The duration of oral-
contraceptive use did not differ significantly between
patients and controls (median, 10 years).
Second-generation oral contraceptives containing
levonorgestrel were used by 24 percent of the patients
and 19 percent of the controls (Table 3). Third-gen-
eration oral contraceptives containing desogestrel or
gestodene were used by 8 percent of the patients and
12 percent of the controls. The odds ratio for myo-
cardial infarction was 2.8 (95 percent confidence in-
terval, 1.3 to 6.3) for women who used first-gener-
ation contraceptives, äs compared with those who had
not used oral contraceptives; 2.4 (95 percent confi-
dence interval, 1.6 to 3.6) for women who had used
second-generation contraceptives; and 1.3 (95 percent
confidence interval, 0.8 to 2.3) for women who had
used third-generation contraceptives (Table 3). When
we restricted this analysis to users of second-genera-
tion oral contraceptives (37 patients and 94 controls)
and third-generation oral contraceptives (18 patients
and 91 controls) that contained 30 /Ltg of ethinyl es-
tradiol, the odds ratios did not change substantially:
2.7 for users of second-generation oral contraceptives
(95 percent confidence interval, 1.6 to 4.3) and 1.6
for users of third-generation oral contraceptives (95
percent confidence interval, 0.9 to 2.9). A direct com-
parison of oral contraceptives containing 30 μ§ of
ethinyl estradiol and levonorgestrel, desogestrel, or
gestodene revealed an odds ratio for myocardial infarc-
tion of 0.5 (95 percent confidence interval, 0.2 to 1.1)
for third-generation äs compared with second-gener-
ation oral contraceptives (after adjustment for strati-
fication variables). The odds ratios were similar for
third-generation brands containing desogestrel or
TABLE 1. CHARACTERISTICS OF 248 WOMEN
WITH A FIRST MYOCARDIAL INFARCTION
AND 925 CONTROL WOMEN.*
CHARACTERISTIC
Age — yr
White race — no (%)
Level of education — no (%)
Pnmary school or less
Secondary school
Higher education or umversity
History of hypertension — no (%)
History of hypercholesterolemia
— no (%)
Histoiy of diabetes — no (%)
Body mass Index




Family history of cardiovascular
disease — no (%)

































*Plus-mmus values are means ±SD Data on the level of
education were missmg for l patient and 5 controls, data on
history of hypertension, history of diabetes, and smoking sta
tus weie missmg for 4 controls, data on history of hypercho-
lesterolemia were missmg for 5 controls, data 011 body-mass
mdex (the weight in kilograms divided by the squarc of the
height in meters) were missmg for 30 controls, and data on
family history ot cardiovascular disease were missmg for 9 pa
tients and 54 controls
gestodene. Further adjustment for confounding did
not affect these estimates (Table 3).
In an analysis that was restricted to the 41 patients
and 104 controls who had used contraceptives with
a second-generation progestagen, äs compared with
those who had not used oral contraceptives, the risk
of myocardial infarction was similar for oral contra-
ceptives with different doses of estrogen. The odds
ratio was 2.0 (95 percent confidence interval, 0.6 to
7.3) for brands containing 50 μ-g of ethinyl estradiol
with levonorgestrel and 2.6 (95 percent confidence
interval, 1.6 to 4.2) for brands containing 30 yu,g of
ethinyl estradiol with levonorgestrel. A direct com-
parison of oral contraceptives containing levonorges-
trel and ethinyl estradiol revealed an odds ratio of 1.7
(95 percent confidence interval, 0.4 to 7.9) for all
brands that contained less than 50 //-g of ethinyl es-
tradiol äs compared with brands diät contained 50 μ§
of ethinyl estradiol or more.
We analyzed the effect of other cardiovascular risk
factors in women who used oral contraceptives, äs
compared with the reference category of women who
had not used oral contraceptives and who did not have
the given risk factor (Table 4). The adjusted odds ra-
tios for myocardial infarction among women who had
not used oral contraceptives were 7.9 (95 percent con-
N Engl J Med, Vol 345, No. 25 · Decembcr 20, 2001 · www.nejm org · 1789
The New England Journal of Medicme
TABLE 2. ODDS RATIOS FOR MYOCARDIAL INFARCTION AMONG WOMEN WHO USED


















































45-49 yr 117 33 (28) 252 41 (16) 2 0 (l 2-3 5) l 7 (0 8-3 3)
Total 245 99 (40) 916 348 (38) 2 0 (l 5-2 8) 2 0 (l 4-3 0)
*For each age group, the women who had not used oral contraceptives servcd äs the reference
group Twelvc women (thrce paticnts and nine controls) were excludcd from the analysis it was not
known whether seven controls had used oral contraceptivcs, and five women used hormonc replacc
ment therapy (three patients and two controls) OC denotes oral contraceptivc, and CI confidence
interval
|Odds ratios were adjusted for the area of residence and calendar ycar
JOdds ratios were adjusted for the area of residence and calendar year, smoking Status, presence
or absence of hypertcnsion, hypercholesterolcmia, diabetcs, obesity (a body mass mdex of at least
273), and a family history of cardiovascular disease, level of education, and alcohol intake
TABLE 3. ODDS RATIOS FOR MYOCARDIAL INFARCTION IN RELATION το THE








































25 (1 5-4 1)
13 (07-25)
21 (07-64)
*For each companson the group of women who had not uscd oral contraceptives (146 paticnts
and 568 controls) served äs the reference group Iwclve women (three patients and nine controls)
wcrc left out of the analysis it was not known whether seven controis had uscd oial contraceptives,
and five women uscd hormone rcplacemcnt therapy (thrcc paticnts and two controls) The type of
01 al contraccptive used was unknown m six controls CI denotes confidence interval
jOdds ratios were adjusted for agc, area of residence, and calendar ycar
JOdds ratios were adjusted for age, area of residence, and calendar year, smoking Status, presence
or absence of hypertension, hypcrcholcsterolemia, diabetes, obesity (a body mass mdex of at least
273), and a family history of cardiovascular discasc, Icvcl of education, and alcohol mtakc
§Tlus category mcluded oral contraceptives containmg an estrogcn and cither cyproteronc or nor
gestimatc or containmg a progestagen alone
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fidence interval, 4.9 to 12.9) for those who smoked,
5.1 (95 percent confidence interval, 2.9 to 8.8) for
those with hypertension, 3.3 (95 percent confidence
interval, 1.6 to 6.8) for those with hypercholesterol-
emia, 4.2 (95 percent confidence interval, 1.6 to 10 9)
for those with diabetes, and 3.4 (95 percent confi-
dence interval, 2.2 to 5.3) for those who were obese.
Among women who had used oral contraceptives, the
risk of myocardial infarction was highest among those
who smoked (odds ratio, 13.6), those who had diabe-
tes (odds ratio, 17.4), and those who had hypercho-
lesterolemia (odds ratio, 24.7).
Factor V Leiden or a G20210A mutation in the
pro thrombin gene was present in 18 of 214 patients
(8 percent) and 58 of 760 controls (8 percent). Two
control women carried both mutations. The odds
ratio for myocardial infarction among women with
a prothrombotic mutation was 1.1 (95 percent con-
fidence interval, 0.6 to 1.9), äs compared with wom-
en without a mutation. In the subgroup of smokers
the presence of one of these mutations increased the
risk of myocardial infarction by 1.6 (95 percent con-
fidence interval, 0.8 to 3.3). Among women young-
er than 35 years of age who had a prothrombotic mu-
tation, the odds ratio was 1.6 (95 percent confidence
interval, 0.4 to 5.8), and among those who were at
least 35 years old it was 0.9 (95 percent confidence
interval, 0.5 to 1.7). The use of oral contraceptives
doubled the risk of myocardial infarction among wom-
en without a prothrombotic mutation (odds ratio, 2.1;
95 percent confidence interval, 1.5 to 3.0) and among
women with a prothrombotic mutation (odds ratio,
1.9; 95 percent confidence interval, 0.6 to 5.5).
DISCUSSION
In this case-control study we found that the use
of currently available combined oral contraceptives
increased the overall risk of a first myocardial infarc-
tion. As compared with nonusers, women who used
first- and second-generation oral contraceptives had
a significantly increased risk, but the results were in-
conclusive for women who used third-generation oral
contraceptives. The risk was increased in all age groups
except for the small group of women who were 18
to 24 years old, and there were no significant differ-
ences in die odds ratios between the age categories
TABLE 4. ODDS RATIOS FOR MYOCARDIAL INFARCTION IN RELATION το THE USE
OF ORAL CONTRACEPTIVES AND το THE PRESENCE OR ABSENGE OF CARDIOVASCULAR RISK FACTORS *
RISK FACTOR No USE OF ORAL CONTRACEPTIVES
PATIENTS CONTROLS ODDS RATIO
(N = 146) (N = 568) (95% CI)
no of women


































































































5 1 (2 7-9 6)
21 (15-30)
19 (06-55)
*Twelve women (thiee patients and nme controls) were lett out of the analysis it was not kiiown whcthcr seven contiols
had used oral contiaceptives, and five women used hormone replacement therapy (thiee patients and two controls) Data
on smoking, hypertension, hypercholesterolemia, and diabetes were missmg foi 2 Lontrols, and data on obcsity were miss
mg tor 27 controls Odds ratios wcrc relative to those of the icfercncc groups (nonusers without the given risk factor)
and were adjusted for age, arca of icsidence, and calcndar year CI denotes confidence interval
|A total of 217 patients and 763 contiols underwent DNA tcstmg, DNA could not bc analyzed m 3 patients and
3 controls
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or between the doses of estrogen. The risks were high-
est among users of oral contraceptives who smoked,
who had diabetes mellitus, or who had hypercholes-
terolemia, but they were not affected by the presence
of factor V Leiden or the G20210A mutation in the
prothrombin gene.
The use of second-generation oral contraceptives
increased the risk of myocardial infarction by a factor
of 2.5. The use of third-generation oral contracep-
tives did not increase the risk significantly (odds ratio,
1.3). The direct comparison of second- and third-gen-
eration oral contraceptives suggested that the use of
third-generation agents was associated with a lower
risk of myocardial infarction, but the confidence 111-
terval was wide and therefore a definite conclusion
could not be reached.
Five studies, including ours, have directly compared
the effect of the use of second- and third-generation
oral contraceptives on the risk of myocardial infarc-
tion,17 21 with reported odds ratios that ranged from
0.318 to 1.8.21 Only the study by Dünn et al.21 and our
study were designed to assess whether the use of third-
generation oral contraceptives has a different effect 011
the risk of myocardial infarction than does the use of
second-generation agents and included a sufficient
number of women who used third-generation oral
contraceptives to allow conclusions to be drawn. Dünn
et al. suggested that the risk is higher with third-gen-
eration than with second-generation oral contracep-
tives (odds ratio, 1.8; 95 percent confidence interval,
0.7 to 4.8), whereas we found the reverse (odds ra-
tio, 0.5; 95 percent confidence interval, 0.2 to 1.1).
As can be seen from the confidence interval, the study
by Dünn et al. also did not permit a definite conclu-
sion to be reached.
Our study was designed äs a nationwide, popula-
tion-based, case-control study, with patients recruit-
ed from all eight academic centers in the Netherlands
and eight surrounding hospitals. One of the strengths
of our study is that the use of both second- and third-
generation oral contraceptives is widespread in the
Netherlands, thus providing a large population of po-
tential study subjects. In the evaluation of our results,
we also need to address the possibility of bias. Because
all patients with known myocardial infarction were
hospitalized and the patients were selected entirely
on the basis of the discharge diagnosis, selection bias
is improbable. The rate of nonresponse was fairly low
and was unlikely to have been associated with the use
of oral contraceptives or the type of agent used. In-
formation bias was unlikely, because the women were
not told about the primary objective of the study and
the questionnaire elicited Information about many
issues. The subjects' recall was optimized by the in-
clusion in the questionnaire of color photographs of
all available oral contraceptives.29 However, the pos-
sibility of recall bias cannot be excluded. Patients who
died after a myocardial infarction were not included
in the study, but it is unlikely that the use of oral con-
traceptives would be a specific contributing factor to
the case fatality rate.
Selective prescription following screening for risk
factors may affect the risks associated with the use of
oral contraceptives. We therefore investigated risk-fac-
tor Status according to the use of oral contraceptives
in the control women and found little difference in
the prevalence of cardiovascular risk factors between
those who used oral contraceptives and those who did
not (Table 5). There were small differences in the in-
cidence of hypercholesterolemia and diabetes and in
body-mass index, which were in part explained by the
younger age of oral-contraceptive users. To minimize
the likelihood of confounding, we also conducted an
analysis restricted to women with no cardiovascular
risk factors and still found that women who used oral
contraceptives had a risk of myocardial infarction that
was three times the risk among nonusers.
Although the risk of myocardial infarction in users
of oral contraceptives is small in absolute terms, it has
an important effect on women's health, since 35 to
TABLE 5. PREVALENCE OF RISK FACTORS FOR CARDIOVASCULAR




Level of cducation — no (%)
Primary school or less
Secondary school
Higher education or university
History of hypertension — no (%)
History of hypercholesterolemia
— no. (%)
History of diabetes — no (%)
Body mass mdcx








Family history of cardiovasculai





































*Plus-mmus valucs arc meatis ±SD Nmc women wcrc excluded π ο m
the analysis it was not known whether scvcn women had used oral contra-
ceptives, and two women used hoimone replaccment thcrapy Data on the
levcl of education were missing foi 3 women who had used oral contraeep-
tivcs and l woman who had not used them, data on smoking Status wcrc
missing for 3 women who had not used oial contraceptives, data on alcohol
mtakc wcrc missing foi 4 women who had used oral contiaccptivcs and
3 women who had not used them, and data on family history of cardiovas-
cular discasc were missing foi 22 women who had used oral contraceptives
and 29 who had not used them
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45 percent of womeii of reproduktive age use oral
contraceptives.30 Because all combined oral contra-
ceptives are equally effective meaiis of birth control,
die issue of safety is paramount. Since die absolute risk
of myocardial iiifarction is highly age-depeiideiit, the
risk associated with die use of oral contraceptives will
have the greatest effect in older women. A large num-
ber of women who were 35 years of age or older still
used oral contraceptives (26 percent). This fmding,
however, may be specific to the Netherlaiids (the
rate is 24 percent in national statistics).30 Before pre-
scribing oral contraceptives, cliiiicians should screeii
women for coiiventional risk factors for cardiovascu-
lar eveiits, and they should remember that the most
importaiit advice they can give these women remains
to quit smokiiig.
Supported by a grant (97-063) irom the Ncthcilands Heait Foundation
Di Helmcihoist has supcrviscd icseaich studies sponsoied by multiple
pharmaceutical conipanies that nianufactuie oral-contiaecptivc agents
We are mdebted to Dr. Bruno Stricker for advice d.unnjj the plan-
mnpj ofthe study, to Dr Jan Vandenbroucke and Dr Tim Farleyfor
entical readmj) ofand advice on the analysis and wnttng, to Anne-
mieke van Dam for her work in contactinjj patients and controls äs
well äs for jjeneral data manqgement, to Esther van Limtercn und
Marjon de Boer for their assistance in rccruiting controh, to Tmeke
Krommenhoek-van Es for the DNA analyses, to Dr Hans Vosfor su-
perviswn, and to all the women who parttcipattd m this project
APPENDIX
The following mvcstigators and ccntcis in the Nctheilands participated
in the study Leiden Umvcrsity Medical Center, Leiden — E E van der
Wall, Sint Antonius Hospital, Nleuwegem — N M van Hemel, Academic
Medical Ceiitei, Amstcidam — R J G Peters, Rrjnstate Hospital, Arnhcm
— H A Boskci, Medical Center Haaglandui, Wcstcinde Hospital, The
Hague — J Kolf, University Medical Ccntei, Nijmegen-St Radboud —
EWA Verheugt, Lcycnburg Hospital, The Hague — B JM Delemane,
University Medical Centei, Rottcrdam-Dljk^lgt — FA M Jonknian, Aca-
dcmic Hospital, Maastnclit — F Veimeei, Rijnland Hospital, Lcideidoip
— C van Rees, Medical Ccntei Eicc University, Amsteidam — O Kamp,
University Medical Centei, Uuecht — E O Robles de Medma (dcceascd),
Academic Hospital, Groningen — M \an den Bcig, Biono\o Hospital,
The Hague — P K M van Dijkman, Sint Fianciscus Hospital, Rottcidam
— A Schclhng, and Diaconessenhuls Leiden — S A G J Witteveen
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